Compare · EVH vs RTO
EVH vs RTO
Side-by-side comparison of Evolent Health Inc (EVH) and Rentokil Initial plc (RTO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVH and RTO operate in Other Consumer Services (Consumer Discretionary), so they compete in similar markets.
- RTO is the larger of the two at $10.50B, about 19.1x EVH ($550.6M).
- RTO has been more active in the news (6 items in the past 4 weeks vs 3 for EVH).
- EVH has more recent analyst coverage (22 ratings vs 16 for RTO).
- Company
- Evolent Health Inc
- Rentokil Initial plc
- Price
- -
- -
- Market cap
- $550.6M
- $10.50B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Other Consumer Services
- Other Consumer Services
- Exchange
- NYSE
- NYSE
- IPO
- 2015
- 2022
- News (4w)
- 3
- 6
- Recent ratings
- 22
- 16
Evolent Health Inc
Evolent Health, Inc., through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates through two segments, Services and True Health. The Services segment provides value-based care services that include Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows and engages patients; population health performance that delivers patient-centric cost effective care; and delivery network alignments. This segment also offers specialty care management solutions that support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation, and specific market dynamics; and comprehensive health plan administrative services that helps providers assemble the complete infrastructure required to operate, manage, and capitalize on a variety of financial and administrative management services. The True Health segment operates a commercial health plan for small and large businesses in New Mexico. Evolent Health, Inc. was founded in 2011 and is headquartered in Arlington, Virginia.
Latest EVH
- Evolent To Release Third Quarter 2026 Financial Results on Thursday, November 5, 2026
- TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation
- TransPerfect Selected by Evolent for Enterprise-Wide Telephonic Interpretation
- Amendment: SEC Form SCHEDULE 13G/A filed by Evolent Health Inc
- PRESIDENT Mccarthy Daniel Joseph sold $329,460 worth of shares (65,892 units at $5.00) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 655,133 units (SEC Form 4)
- Evolent Health upgraded by Citigroup with a new price target
- SEC Form 10-Q filed by Evolent Health Inc
- Evolent Health Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Evolent Announces Second Quarter 2026 Results
- Evolent Health downgraded by Citigroup with a new price target
Latest RTO
- SEC Form 6-K filed by Rentokil Initial plc
- Rentokil Initial plc upgraded by Stifel
- Detroit Climbs into Terminix’s Top 10 as Fall Rodent Pressure Shifts Nationwide
- SEC Form 6-K filed by Rentokil Initial plc
- Rentokil Initial plc downgraded by Morgan Stanley
- SEC Form 6-K filed by Rentokil Initial plc
- SEC Form 6-K filed by Rentokil Initial plc
- SEC Form 6-K filed by Rentokil Initial plc
- SEC Form 6-K filed by Rentokil Initial plc
- SEC Form 6-K filed by Rentokil Initial plc